123rd General Meeting of the KCS

Type Symposium
Area Recent Trends in Biopharmaceuticals Research
Room No. Room 303
Time THU 16:40-17:10
Code LIFE1-3
Subject Development of next-generation therapeutic antibodies through directed evolution
Authors Sang Taek Jung
Department of Applied Chemistry, Kookmin University, Korea
Abstract IgG antibodies have been widely capitalized for therapeutics, diagnostics, and biomedical research reagents due to their outstanding target specificity and evolvability. For efficient isolation of monoclonal antibodies against highly valuable targets (e.g., soluble oncogenic targets, receptors, toxins, etc.) in a high throughput manner, we have constructed multiple human antibody libraries, which have a vast diversity of over 1× 1011, and have successfully utilized them for the isolation of monoclonal antibodies against highly challenging target antigens including G protein-coupled receptors. After binding to antigen, antibody Fc region determines therapeutic efficacy and serum half-life by the interaction with the Fc binding ligands such as FcγRs (Fc gamma receptors), serum complement molecules, and FcRn (neonatal Fc receptor). To overcome the limitation of conventional monoclonal antibodies used in the clinical practice, engineering efforts in the last several years opened a new gateway to transform IgG Fc into a highly evolvable unit for a new desired function. To enhance therapeutic efficacy and circulating half-life, we have employed a variety of genetic, cellular and evolutionary strategies and the results will be discussed.
E-mail sjung@korea.ac.kr